Recent Company News

• 12:11 PM ET Oct 08, 2026
  

  StreetAccount Summary - U.S. Unusual Option Volume: VIX +3.1% to 15.54; S&P 500 (0.4%) to 7,774.51

• 07:04 AM ET Sep 09, 2026
  

  Autolus Therapeutics announces FDA RMAT designation granted to obe-cel for treatment of SLE and LN ($2.11, 0.00)

• 11:25 AM ET Aug 04, 2026
  

  StreetAccount Summary - US unusual volume traders

• 10:00 AM ET Aug 11, 2026
  

  Transcript Intelligence: Autolus Therapeutics Q2 Earnings Guidance ($2.32, +0.25)

• 09:59 AM ET Aug 11, 2026
  

  Transcript Intelligence: Autolus Therapeutics Q2 Earnings Q&A ($2.33, +0.26)

• 09:59 AM ET Aug 11, 2026
  

  Transcript Intelligence: Autolus Therapeutics Q2 Earnings Themes ($2.33, +0.26)

• 07:04 AM ET Aug 11, 2026
  

  Autolus Therapeutics reports Q2 EPS ($0.15) vs FactSet ($0.19) [7 est, ($0.22)-(0.18)] ($2.07, 0.00)

• 09:15 AM ET Aug 03, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 07:20 AM ET Aug 03, 2026
  

  Autolus Therapeutics reports preliminary Q2 2026 net product revenue; announces credit facility of up to $250M with Perceptive Advisors ($1.49, 0.00)